Navigation Links
Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
Date:12/6/2012

s being held December 2-6, 2012 in Hollywood, Florida.  For more information, visit www.acnp.org/annualmeeting/default.aspx.

About Naurex
Naurex Inc. is a clinical-stage private company developing novel therapies to address unmet needs in psychiatry and neurology based on a new mechanism of action for modulating the NMDA receptor in a safe way.  Naurex's lead product, GLYX-13, has shown promising antidepressant activity with excellent safety in a Phase II trial, confirming the efficacy signals and safety observed in Phase I and preclinical studies.  In a Phase II trial in subjects who had failed treatment with one or more antidepressant agents, a single administration of GLYX-13 produced statistically significant reductions in depression scores within 24 hours, which persisted for an average of seven days.  Naurex's second-generation programs include a number of molecules with preclinical proof of concept.  The company's patented novel chemistry classes represent a platform for the development of new therapies for a variety of CNS disorders.  For more information about Naurex, visit www.naurex.com. Contacts:

MediaNaurex Inc.

BLL Partners, LLCAshish Khanna

Barbara LindheimVice President, Corporate Development

(212) 584-2276(847) 871-0377

blindheim@bllbiopartners.comcorporate@naurex.com
'/>"/>

SOURCE Naurex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
2. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
5. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
6. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
7. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
8. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
9. A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
10. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
11. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Sodium ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/21/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 30, 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A ... Summary:Three-months ended September 30, , Nine-months ended ... 2014 , 2013 , 2014 ... , 6,715 , 14,476 Gross profit , ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring Dr. ... in the Regulatory Biology Laboratory at the Salk Institute, studies ... an “off switch” for drug resistance in cancer. , Learn ... is making a global impact in the fight against cancer. ... Cheryl K. Goodman, CEO of Social Global Mobile LLC, for ...
(Date:11/18/2014)... 18, 2014 Array Architects is proud ... expertise to the nation's hospitals and health systems. It ... those dedicating their careers to the advancement of both ... in her respective field, Laura Silvoy has been chosen ... 2014 Winter Simulation Conference. , Laura will present ...
Breaking Biology Technology:Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2
... Fourth Quarter Highlights:, -- Record revenues of $82.0 million, up 22% from the prior year,s fourth ... quarter ... $0.23, a 130% increase over last year,s ... of $24.3 million, revolving debt facility paid off, -- Launch of four new food and beverage products and ...
... WILMINGTON, N.C., Dec. 12 PPD, Inc. ... M.D., as director,of strategic development, to lead the ... Dr. Mathew will provide strategic leadership for PPD,s ... project management,and patient recruitment for key therapeutic areas. ...
... 12 Beckman Coulter,Inc. (NYSE: BEC ), ... complex biomedical testing, announced today that Susan R.,Nowakowski, ... Services, Inc. (NYSE: AHS ) has been ... effective December 10., (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ...
Cached Biology Technology:Martek Announces Fourth Quarter and FY 2007 Financial Results 2Martek Announces Fourth Quarter and FY 2007 Financial Results 3Martek Announces Fourth Quarter and FY 2007 Financial Results 4Martek Announces Fourth Quarter and FY 2007 Financial Results 5Martek Announces Fourth Quarter and FY 2007 Financial Results 6Martek Announces Fourth Quarter and FY 2007 Financial Results 7Martek Announces Fourth Quarter and FY 2007 Financial Results 8Martek Announces Fourth Quarter and FY 2007 Financial Results 9Martek Announces Fourth Quarter and FY 2007 Financial Results 10Martek Announces Fourth Quarter and FY 2007 Financial Results 11Martek Announces Fourth Quarter and FY 2007 Financial Results 12Martek Announces Fourth Quarter and FY 2007 Financial Results 13Martek Announces Fourth Quarter and FY 2007 Financial Results 14Martek Announces Fourth Quarter and FY 2007 Financial Results 15Mathew to Lead PPD Drug Development Operations and Expansion in India 2Mathew to Lead PPD Drug Development Operations and Expansion in India 3Beckman Coulter Elects AMN Healthcare Executive to Board of Directors 2
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
(Date:11/2/2014)... issue of Physics World , James Dacey explores ... of death" to take their innovations from the lab ... gruelling challenge facing all start-up companies as they move ... because of two main factors: physics-based inventions are usually ... turn out to be a lot more complicated than ...
(Date:11/2/2014)... to put a flashlight up to our palms to ... in St. Louis engineers are using a similar idea ... imaging of cancerous tissues and to develop potential treatments. ... Distinguished Professor of Biomedical Engineering at the School of ... technology that allows researchers to better focus light in ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
... KAN. -- It,s a cloak that surpasses all others: ... change the way bacteria and other cells are imaged. ... Kansas State University, and his research team are wrapping ... bacteria under electron microscopes. Berry,s method creates a carbon ...
... 15In the latest twist on optical knots, New York ... create extended and knotted optical traps in three dimensions. ... Optical Society,s (OSA) open-access journal Optics Express , ... intensity traces out a knotted trajectory in space, for ...
... variety of plant seedlings suffer most from competition when planted ... relatives in field soils, researchers from Case Western Reserve University ... when seeds of the same species are buried among relatives ... and grow better early in life in close relatives, habitats ...
Cached Biology News:All wrapped up: K-State researcher's graphene cloak protects bacteria, leading to better images 2All wrapped up: K-State researcher's graphene cloak protects bacteria, leading to better images 3Tying the knot with computer-generated holograms: Winding optical path moves matter 2Tying the knot with computer-generated holograms: Winding optical path moves matter 3Seedlings thrive with distant relatives, seeds with close family 2
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
Biology Products: